Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108090 · ClinicalTrials.gov registry record · NA
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
A NA study of Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT05108090: Recruiting NA study of Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, sponsored by Indiana University.
NCT05108090 is a NA study of Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma that is actively recruiting participants, run by Indiana University. The registered enrollment target is 94 participants, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05108090, a NA study of Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.
Primary Outcome
Incidence of occult metastasis in cT2-4N0 cutaneous squamous cell carcinoma (cSCC) of the head and neck by measuring the number of patients with positive sentinel lymph node biopsies.
Conditions Studied
Interventions
- PROCEDURE sentinel lymph node biopsy (SLNB)
Study Locations (1)
Indiana
- Indiana University Melvin & Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT05108090 shows while recruiting
NCT05108090 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target.
The record links to 3 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which sentinel lymph node biopsy (SLNB) is the first listed.
NCT05108090 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT05108090 about?
NCT05108090 is a clinical study titled "Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck". The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.
What is the current status of trial NCT05108090?
This trial is currently recruiting. It is a NA study. The enrollment target is 94 participants. The study started on 2021-10-25. Estimated completion is 2026-09.
What conditions does trial NCT05108090 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancer.
What interventions are being tested in trial NCT05108090?
The interventions under investigation include: sentinel lymph node biopsy (SLNB) (PROCEDURE).
Who is sponsoring clinical trial NCT05108090?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05108090 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05108090's enrollment target sits among peer trials
94 13th of 47 higher than 35 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
RECRUITING · NA
-
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
ACTIVE NOT RECRUITING · NA
-
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
ACTIVE NOT RECRUITING · NA
-
Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
COMPLETED · NA
-
Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx
COMPLETED · NA
-
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI